| 03 Novembre 2016
CentoMD®, the world’s  largest genomic database for rare disease, maintains with its recent  release v3.1 approx. 3 million identified alleles, disease-associated  polymorphisms, benign polymorphisms and other known variants of  undetermined significance, thereof 57% of unpublished data. CentoMD®  encompasses genetic information and clinical data from more than 100,000  people worldwide. “The fast grown era of mass data produced by whole exome and whole  genome sequencing demands unprecedented access to all available  information within the shortest time. The collaboration with IBS will  clearly reduce the time for diagnostic workflows needed for making sound  decisions of clinical relevance. Furthermore, especially in those  ethnicities typically not adequately represented in existing data banks,  like Canadian, Latin American or Arabic, the collaboration will  increase the quality of all diagnostic processes.”, stated Prof. Arndt  Rolfs, CEO of Centogene AG. Alamut Visual is a  decision-support software application that integrates genomic  information from different sources and prediction algorithms in one  convenient environment to describe variants and helps interpret their  pathogenic status. Alamut® Visual is used by clinical and research  molecular laboratories worldwide. It is the software of choice for  leading university medical centers, hospitals, and private human genome  laboratories. “We are keen on providing  clinical users with the most relevant and extensive data sets to help  them in the complex task of interpreting genomic variations. By  enriching Alamut® Visual with CentoMD variants, we expect to increase  Rare Disease scientists’ ability to efficiently assess variants,  especially in populations insufficiently represented in other  databases.”, said André Blavier, CEO of Interactive Biosoftware. CENTOGENE and IBS are looking forward to helping interpret the  pathogenic status of detected genetic variants, with special focus on  not yet published data. About Interactive Biosoftware IBS, the software company  located in France, offers a complete solution to the tasks of variant  annotation, filtration, interpretation and reporting with the Alamut  Software Suite. IBS is changing genetic diagnostics and research as we  know it by simplifying the mutation interpretation process, while saving  scientists time, improving outcome quality and enhancing productivity. For more information, please visit www.interactive-biosoftware.com
Centogene AG (CENTOGENE) and Interactive Biosoftware (IBS) announce to  start their collaboration on the integration of CENTOGENE’s unique  genomic database CentoMD® and Alamut® Visual, the decision-support  software from IBS. With joining forces for providing genetic variant  interpretation data, both companies expand the support for the medical  community to reach the most complete information at one spot. 









